PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 5993人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255155, encodeId=57eb1255155ba, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏PD-L1+TIGIT一线治疗NSCLC，期中分析发现PFS未获益，仍然期待OS终点的数据表现, objectType=article, longId=726686, objectId=ead0e2668637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ead0e2668637, replyNumber=0, likeNumber=79, createdTime=2022-05-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ead0e2668637, moduleTitle=罗氏PD-L1+TIGIT一线治疗NSCLC，期中分析发现PFS未获益，仍然期待OS终点的数据表现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ead0e2668637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255156, encodeId=d0a41255156e2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, objectType=article, longId=726424, objectId=b321e2642494, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b321e2642494, replyNumber=0, likeNumber=77, createdTime=2022-05-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b321e2642494, moduleTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b321e2642494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255154, encodeId=0b081255154f2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1 vs PD-L1，肿瘤免疫治疗，谁的效果好？, objectType=article, longId=725832, objectId=ce83e25832e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce83e25832e8, replyNumber=0, likeNumber=83, createdTime=2022-05-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce83e25832e8, moduleTitle=PD-1 vs PD-L1，肿瘤免疫治疗，谁的效果好？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce83e25832e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255153, encodeId=3ebf12551533e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=一图读懂 | 国内批准的13款PD-1/PD-L1药物, objectType=article, longId=725741, objectId=f30fe2574124, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f30fe2574124, replyNumber=0, likeNumber=75, createdTime=2022-04-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f30fe2574124, moduleTitle=一图读懂 | 国内批准的13款PD-1/PD-L1药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f30fe2574124)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255152, encodeId=754c12551520e, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=免疫检查点PD-L1免疫组化检测方法及结果判定, objectType=article, longId=724937, objectId=5dc8e2493766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dc8e2493766, replyNumber=0, likeNumber=84, createdTime=2022-04-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dc8e2493766, moduleTitle=免疫检查点PD-L1免疫组化检测方法及结果判定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dc8e2493766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255151, encodeId=4d53125515172, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=《科学》子刊：抗癌明星PD-L1竟然还是“减重大师”！科学家发现，脂肪DC细胞通过PD-L1调控体重, objectType=article, longId=724542, objectId=f0f1e24542d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0f1e24542d9, replyNumber=0, likeNumber=124, createdTime=2022-04-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0f1e24542d9, moduleTitle=《科学》子刊：抗癌明星PD-L1竟然还是“减重大师”！科学家发现，脂肪DC细胞通过PD-L1调控体重, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0f1e24542d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255150, encodeId=b988125515062, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1/PD-L1药物治疗起效后，何时能停？获批适应证有哪些？, objectType=article, longId=724077, objectId=f67de2407786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f67de2407786, replyNumber=0, likeNumber=77, createdTime=2022-04-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f67de2407786, moduleTitle=PD-1/PD-L1药物治疗起效后，何时能停？获批适应证有哪些？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f67de2407786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255149, encodeId=f679125514967, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, objectType=article, longId=723967, objectId=4b52e23967b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b52e23967b8, replyNumber=0, likeNumber=87, createdTime=2022-04-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b52e23967b8, moduleTitle=AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b52e23967b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255147, encodeId=29f4125514e42, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌, objectType=article, longId=723589, objectId=d350e23589a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d350e23589a7, replyNumber=0, likeNumber=67, createdTime=2022-04-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d350e23589a7, moduleTitle=Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d350e23589a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255148, encodeId=52721255148c1, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）, objectType=article, longId=723564, objectId=5743e2356484, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5743e2356484, replyNumber=0, likeNumber=86, createdTime=2022-04-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5743e2356484, moduleTitle=Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5743e2356484)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255146, encodeId=154b1255146b3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1/PD-L1药物大盘点——K、O、T、B、I、L、J 药, objectType=article, longId=301900, objectId=630c30190038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=630c30190038, replyNumber=0, likeNumber=97, createdTime=2022-03-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=630c30190038, moduleTitle=PD-1/PD-L1药物大盘点——K、O、T、B、I、L、J 药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=630c30190038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255145, encodeId=7e2f12551450f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=72, createdTime=2022-03-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255144, encodeId=ed83125514479, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=减肥全新途径：PD-L1除了用来抗癌，还可作为肥胖治疗靶点, objectType=article, longId=301414, objectId=fbb5301414c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbb5301414c5, replyNumber=0, likeNumber=100, createdTime=2022-03-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbb5301414c5, moduleTitle=减肥全新途径：PD-L1除了用来抗癌，还可作为肥胖治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbb5301414c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255143, encodeId=17e5125514356, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗, objectType=article, longId=300793, objectId=c77e300e932f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c77e300e932f, replyNumber=0, likeNumber=83, createdTime=2022-03-16, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77e300e932f, moduleTitle=PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c77e300e932f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255142, encodeId=43af1255142dd, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡, objectType=article, longId=300374, objectId=81c23003e459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81c23003e459, replyNumber=0, likeNumber=85, createdTime=2022-03-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81c23003e459, moduleTitle=条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81c23003e459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255141, encodeId=64e81255141e1, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, objectType=article, longId=299549, objectId=91b029954956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b029954956, replyNumber=0, likeNumber=93, createdTime=2022-02-25, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b029954956, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b029954956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255140, encodeId=f56e125514048, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-1单药使用总体疗效为什么那么低? 此处无关PD-L1是否表达, objectType=article, longId=295371, objectId=d9b52953e178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9b52953e178, replyNumber=0, likeNumber=53, createdTime=2022-02-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9b52953e178, moduleTitle=PD-1单药使用总体疗效为什么那么低? 此处无关PD-L1是否表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9b52953e178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255139, encodeId=6c1512551398c, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, objectType=article, longId=295314, objectId=762829531471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=762829531471, replyNumber=0, likeNumber=61, createdTime=2022-02-10, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=762829531471, moduleTitle=Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=762829531471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255138, encodeId=ac6212551388d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, objectType=article, longId=295174, objectId=ce4f2951e4a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4f2951e4a6, replyNumber=0, likeNumber=76, createdTime=2022-02-07, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4f2951e4a6, moduleTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4f2951e4a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255137, encodeId=c543125513e89, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, objectType=article, longId=295140, objectId=2fc82951409c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc82951409c, replyNumber=0, likeNumber=92, createdTime=2022-02-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc82951409c, moduleTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc82951409c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏PD-L1+TIGIT一线治疗NSCLC，期中分析发现PFS未获益，仍然期待OS终点的数据表现

2022-05-13

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效

2022-05-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1 vs PD-L1，肿瘤免疫治疗，谁的效果好？

2022-05-01

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

一图读懂 | 国内批准的13款PD-1/PD-L1药物

2022-04-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

免疫检查点PD-L1免疫组化检测方法及结果判定

2022-04-26

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

《科学》子刊：抗癌明星PD-L1竟然还是“减重大师”！科学家发现，脂肪DC细胞通过PD-L1调控体重

2022-04-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1/PD-L1药物治疗起效后，何时能停？获批适应证有哪些？

2022-04-13

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

AACR重磅之KEYNOTE-042：帕博丽珠单抗持续延长了中国晚期/转移性PD-L1阳性NSCLC患者的生存期——Keynote-042中国研究的4年随访数据结果

2022-04-12

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌

2022-04-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）

2022-04-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1/PD-L1药物大盘点——K、O、T、B、I、L、J 药

2022-03-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2022-03-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

减肥全新途径：PD-L1除了用来抗癌，还可作为肥胖治疗靶点

2022-03-24

zhouqu_8 (审核中...)

前往app查看评论内容

#PD-L1#

PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗

2022-03-16

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡

2022-03-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

2022-02-25

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-1单药使用总体疗效为什么那么低? 此处无关PD-L1是否表达

2022-02-11

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Transl Lung Cancer Res: PD-L1表达水平与III期NSCLC患者使用durvalumab（德瓦鲁单抗）维持治疗疗效的关系

2022-02-10

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性

2022-02-07

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？

2022-02-06

科室
- - 订阅+
  - 更多科室
工具
服务